Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

UDENYCA® is a pegfilgrastim biosimilar used to reduce the chance of infection in patients with some tumors. Coherus BioSciences, headquartered in Redwood (NYSE:RWT) City, California, is known for ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

R-EPOCH is primarily used to treat B-cell non-Hodgkin’s lymphoma. It may also be used alongside other drugs or therapies to treat other types of cancer. Researchers are currently studying its ...

This strategic move involves Coherus divesting its UDENYCA® franchise to Intas, a company incorporated in India. UDENYCA® is a pegfilgrastim biosimilar used to reduce the chance of infection in ...

Coherus BioSciences, Inc. ( NASDAQ: CHRS) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, ...

Learn more about whether GE HealthCare Technologies Inc. or Insulet Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.